EXICURE INC
XCURNASDAQTrading Snapshot
- Day Range
- $1.32 – $1.36
- 52-Week Range
- $1.27 – $9.48
- Volume
- $4.65B
- Avg Volume
- $4.66B
- Shares Outstanding
- 6.4M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $573,166
- Last Q Revenue
- $129,072
- P/E Ratio
- —
- P/S Ratio
- 17.5x
- EPS (TTM)
- $-1.54
- Dividend Yield
- —
Why Investors Own XCUR
- ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EXICURE INC
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th
Exicure Plans To Issue 172,058 Common Shares To GPCR Therapeutics During This Month To Settle $1M Clinical Milestone Payment Obligation
Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. ("GPCR Therapeutics") during August
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock moved
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved upwards by
These stocks are moving in today's after hours session
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI) stock increased